Curasight A/S
Copenhagen
About Curasight A/S
Curasight is a biotech company focused on addressing the need for improved diagnosis and treatment of several cancer indications. The Company has developed a highly specific PET (Positron emission tomography) imaging ligand, uTRACE®, targeting the receptor uPAR, which is a biomarker only expressed in cancer. uTRACE® will become a game-changer in the diagnosis and treatment of cancer patients. In addition, with the promising results obtained within diagnostics Curasight will also pursues uPAR targeted radionuclide therapy using the uTREAT® ligand. As PET imaging and radionuclide therapy is based on the same uPAR binding peptide, a uTRACE® scan can precisely predict where subsequent targeted radiation therapy will be delivered. uTRACE® covers the diagnostic path and uTREAT® covers the therapy. This will be the new management and treatment of cancer patients in the future.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $13.6M
- Funding stage: IPO
- Last round: Post-IPO Debt (Dec 2025)
- Ticker: cph:CURAS
- Website: curasight.com
- Phone: +45 22830160
Industries & Categories
Biotechnology, Collaboration, Pet
Social Profiles
Canonical: https://fsome.com/organization/curasight-a-s-88808 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.